Clinical Trials
Pumitamig vs. Durvalumab w/unresectable Stage II NSCLC w/o progression after platinum based concurrent chemoradiation
Disease Type: Lung
A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.inum-based, concurrent chemoradiation therapy
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville